These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22653949)

  • 1. FCA: forget chemoimmunotherapy with alemtuzumab?
    Hallek M
    Blood; 2012 May; 119(22):5059-60. PubMed ID: 22653949
    [No Abstract]   [Full Text] [Related]  

  • 2. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
    Geisler CH; van T' Veer MB; Jurlander J; Walewski J; Tjønnfjord G; Itälä Remes M; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MC; Doorduijn J; Ghidey Alemayehu W; van Oers MH
    Blood; 2014 May; 123(21):3255-62. PubMed ID: 24735962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.
    Mozas P; Rivas-Delgado A; Baumann T; Villamor N; Ortiz-Maldonado V; Aymerich M; Costa D; Navarro A; Giné E; López-Guillermo A; Montserrat E; Delgado J
    Blood Cancer J; 2018 Jan; 8(1):10. PubMed ID: 29339727
    [No Abstract]   [Full Text] [Related]  

  • 4. All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.
    Cheah CY; Lew TE; Lee R; Tam CS; Seymour JF; Carney DA
    Eur J Haematol; 2013 Aug; 91(2):189-90. PubMed ID: 23668259
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
    Winqvist M; Palma M; Heimersson K; Mellstedt H; Österborg A; Lundin J
    Br J Haematol; 2018 Aug; 182(4):590-594. PubMed ID: 28677818
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
    Feugier P; Aurran T; Mahé B; Letestu R; Nguyen-Khac F; Cazin B; Tournilhac O; Maisonneuve H; Casasnovas O; Delmer A; Leblond V; Royer B; Corront B; Chevret S; Delépine R; Vaudaux S; Van Den Neste E; Béné MC; Cymbalista F; Ross-Weil D; Leprêtre S
    Haematologica; 2018 Jul; 103(7):e304-e306. PubMed ID: 29545348
    [No Abstract]   [Full Text] [Related]  

  • 8. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
    Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
    [No Abstract]   [Full Text] [Related]  

  • 9. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?
    Jain N; OʼBrien S
    Cancer J; 2019; 25(6):374-377. PubMed ID: 31764117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
    Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
    Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
    Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL).
    Bloor A; De Cock E; Hatswell AJ; Wasiak R; Elvidge J; Stapelkamp C; Hadjivassileva T; Haiderali A; Delgado J
    Br J Haematol; 2015 May; 169(3):449-52. PubMed ID: 25410960
    [No Abstract]   [Full Text] [Related]  

  • 15. [Chronic lymphocytic leukemia].
    Aoki S
    Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
    [No Abstract]   [Full Text] [Related]  

  • 16. How to improve the treatment outcome in chronic lymphocytic leukemia?
    Robak T
    Leuk Res; 2010 Mar; 34(3):272-5. PubMed ID: 19682742
    [No Abstract]   [Full Text] [Related]  

  • 17. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
    Kay NE; LaPlant BR; Pettinger AM; Call TG; Leis JF; Ding W; Parikh SA; Conte MJ; Bowen DA; Shanafelt TD
    Expert Rev Hematol; 2018 Apr; 11(4):337-349. PubMed ID: 29460654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.
    Zent CS; Call TG; Bowen DA; Conte MJ; LaPlant BR; Witzig TE; Ansell SM; Weiner GJ
    Leuk Lymphoma; 2015; 56(8):2373-8. PubMed ID: 25676035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
    Elter T; James R; Busch R; Winkler D; Ritgen M; Böttcher S; Kahl C; Gassmann W; Stauch M; Hasan I; Staib P; Fischer K; Fink AM; Bahlo J; Bühler A; Döhner H; Wendtner CM; Stilgenbauer S; Engert A; Hallek M
    Leukemia; 2012 Dec; 26(12):2549-52. PubMed ID: 22584787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.